Sensei Biotherapeutics is abandoning its sole clinical-stage drug and warning of imminent layoffs as the company mulls its ...

Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study. | ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Boehringer Ingelheim has returned to Kyowa Kirin for a 640 million euro ($743 million) deal for a preclinical program the German pharma hopes will offer a new autoimmune disease option. | Boehringer ...

Roche has headed back to China to pen a licensing deal worth over $1 billion biobucks for the rights to a clinical-stage bispecific antibody for respiratory diseases. | Roche has headed back to China ...

Roche’s Genentech unit is laying off staff at its Bay Area headquarters for at least the third time this year, saying goodbye ...

AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago ...

Secondary endpoints “indicate symptom reduction and patient benefit beyond improvement in disease activity,” according to ...

Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...

The deal is mainly focused on Incyte’s investigational mutant calreticulin selective monoclonal antibody treatment for the blood disorder essential thrombocythemia and the chronic bone marrow disorder ...

Kyverna saw an 8-point improvement on the MG-ADL scale, which measures the impact of gMG on daily functions, in the three ...